• 1
    Yap YG, Duong T, Bland M, et al. Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. Eur Heart J 2005; 26: 13851393.
  • 2
    Drögemüller A, Seidl K, Schiele R, et al. Prognostic value of non-sustained ventricular tachycardias after acute myocardial infarction in the thrombolytic era: importance of combination with frequent ventricular premature beats. Z Kardiol 2003; 92: 164172.
  • 3
    Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 7: 12A16A.
  • 4
    Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563575.
  • 5
    Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 13551364.
  • 6
    Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005; 111: 30253033.
  • 7
    Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 8085.
  • 8
    Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 12431248.
  • 9
    Beck L, Blanc-Guillemaud V, Cherif OK, et al. Effects of spironolactone and fosinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. Cardiology 2001; 96: 8593.
  • 10
    Yang SS, Han W, Zhou HY, et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin Med J (Engl) 2008; 121: 3842.
  • 11
    De Mello WC. Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. J Renin Angiotensin Aldosterone Syst 2006; 7: 4046.
  • 12
    Stambler BS, Laurita KR, Shroff SC, et al. Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure. Heart Rhythm 2009; 6: 776783.
  • 13
    Shroff SC, Ryu K, Martovitz NL, et al. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 2006; 17: 534541.
  • 14
    Cittadini A, Monti MG, Isgaard J, et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res 2003; 58: 555564.
  • 15
    Pitt B, Zannad F, Remme WJ, et al; for Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709717.
  • 16
    Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 13091321.
  • 17
    Gao X, Peng L, Adhikari CM, et al. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail 2007; 13: 170177.
  • 18
    Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 76: 12591265.
  • 19
    Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000; 85: 12071211.
  • 20
    Shah NC, Pringle SD, Donnan PT, et al. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens 2007; 25: 23452351.
  • 21
    Skvortsov AA, Mareev V, Orlova Ia A, et al. Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy[in Russian]. Kardiologiia 2008; 48: 5264.
  • 22
    Anand K, Mooss AN, Mohiuddin SM. Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure. J Renin Angiotensin Aldosterone Syst 2006; 7: 1519.
  • 23
    Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 18321839.
  • 24
    Muto T, Ueda N, Opthof T, et al. Aldosterone modulates I(f) current through gene expression in cultured neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2007, 293: H27102718.
  • 25
    Crippa G, Sverzellati E, Giorgi-Pierfranceschi M, et al. Magnesium and cardiovascular drugs: interactions and therapeutic role. Ann Ital Med Int 1999; 14: 4045.